Related Experiment Video

Updated: Jan 9, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

858

Outcomes of people living with acute lymphoblastic leukemia who received inotuzumab ozogamicin before a stem cell

Marcos de Lima1, Partow Kebriaei2, Francesco Lanza3

  • 1Ohio State University, Blood and Marrow and Cellular Therapy Program, Columbus, OH, USA.

Future Oncology (London, England)
|December 8, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
HematologicHematologic/LeukemiaImmunotherapyReal-world evidenceTransplantation

More Related Videos

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.2K
Rapid in vivo Drug Response Prediction Using Leukemia Cell Grafts in Zebrafish Embryos
10:46

Rapid in vivo Drug Response Prediction Using Leukemia Cell Grafts in Zebrafish Embryos

Published on: May 23, 2025

860

Related Experiment Videos

Last Updated: Jan 9, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

858
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.2K
Rapid in vivo Drug Response Prediction Using Leukemia Cell Grafts in Zebrafish Embryos
10:46

Rapid in vivo Drug Response Prediction Using Leukemia Cell Grafts in Zebrafish Embryos

Published on: May 23, 2025

860

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

829
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
829

Articles linked to this work by shared authors, journal, and citation graph.

One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T-cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized-controlled trial.

HemaSphere·2026

Outcomes by Body Mass Index in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin.

Targeted oncology·2026

CEACAM5 as a biomarker of semi-solid, lepidic lung adenocarcinoma.

Translational lung cancer research·2026

Fluoroquinolone Prophylaxis Uncovers High Prevalence Rates of Fluoroquinolone-Resistant Enterobacterales Colonization in Multiple Myeloma Autologous Transplant Patients: A Prospective Cohort Study.

Cancers·2026

Elranatamab: Mechanism of Action, Clinical, and Translational Science.

Clinical and translational science·2026

TIGIT agonism as a therapeutic strategy to suppress inflammation in hidradenitis suppurativa.

Frontiers in immunology·2026

First-line osimertinib with or without chemotherapy for EGFR-mutant advanced NSCLC in China: a cost-effectiveness analysis.

Future oncology (London, England)·2026

TroFuse-032 study design: pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy as neoadjuvant therapy for early-stage, triple-negative breast cancer or HR-low+/HER2- breast cancer.

Future oncology (London, England)·2026

Interleukin-6 as a prognostic biomarker in repatocellular carcinoma treated with systemic therapy: a systematic review and meta-analysis.

Future oncology (London, England)·2026

Patient experiences and unmet needs in diagnosis and treatment of metastatic colorectal cancer: results of a US survey.

Future oncology (London, England)·2026

Evaluating taletrectinib in the treatment of patients with ROS1 fusion-positive non-small cell lung cancer.

Future oncology (London, England)·2026

Tissue-based PEG10 expression as an exploratory biomarker associated with first-line R-CHOP treatment outcome in diffuse large B-cell lymphoma.

Future oncology (London, England)·2026

Protection of Bevacizumab From Silicone Oil-Induced Inactivation by Liposomal Encapsulation.

Translational vision science & technology·2026

From immune heterogeneity to targeted therapies in IgG4-related disease.

Current opinion in rheumatology·2026

Teclistamab Induced a Profound Hematologic Response in Light Chain Deposition Disease With Probable Cardiac Involvement.

Hematological oncology·2026

Bispecific antibodies targeting TL1A and IL-12/23p40 suppress pathogenic Th1/Th17 responses and ameliorate colitis in mice.

iScience·2026

Comparative Efficacy and Safety of Bruton Tyrosine Kinase and Spleen Tyrosine Kinase Inhibitors in Immune Thrombocytopenia: A Network Meta-Analysis of Clinical Trials.

EJHaem·2026

Iatrogenic Pseudoaneurysm After Arthroscopic Knee Procedures: A Systematic Review of Presenting Features, Injured Vessels, Management, and Outcomes.

Cureus·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us